Imperial Ginseng Products Balance Sheet Health

Financial Health criteria checks 6/6

Imperial Ginseng Products has a total shareholder equity of CA$265.1K and total debt of CA$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CA$299.7K and CA$34.6K respectively.

Key information

Debt to equity ratio

CA$0

Debt

Interest coverage ratio	n/a
Cash	CA$274.42k
Equity	CA$265.08k
Total liabilities	CA$34.57k
Total assets	CA$299.65k

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: IGP's short term assets (CA$299.7K) exceed its short term liabilities (CA$34.6K).

Long Term Liabilities: IGP has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: IGP is debt free.

Reducing Debt: IGP has no debt compared to 5 years ago when its debt to equity ratio was 10.7%.

Debt Coverage: IGP has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: IGP has no debt, therefore coverage of interest payments is not a concern.

Imperial Ginseng Products Balance Sheet Health

Financial Health criteria checks 6/6

Key information

Recent financial health updates

Recent updates

First half 2024 earnings released: CA$0.005 loss per share (vs CA$0 in 1H 2023)

Upcoming dividend of CA$2.25 per share

Imperial Ginseng Products Ltd. Announces Cash Distribution, Payable on January 26, 2024

Investor sentiment improves as stock rises 27%

New major risk - Market cap size

Insufficient new directors

First quarter 2024 earnings released: CA$0.015 loss per share (vs CA$0.11 loss in 1Q 2023)

New major risk - Market cap size

Insufficient new directors

Here's Why We Think Imperial Ginseng Products (CVE:IGP) Is Well Worth Watching

Full year 2023 earnings released: EPS: CA$0.38 (vs CA$0.31 in FY 2022)

Imperial Ginseng Products Ltd., Annual General Meeting, Dec 07, 2023

Insufficient new directors

Third quarter 2023 earnings released: CA$0.03 loss per share (vs CA$0.05 loss in 3Q 2022)

Insufficient new directors

Investor sentiment improves as stock rises 19%

Second quarter 2023 earnings released: EPS: CA$0.11 (vs CA$0.07 loss in 2Q 2022)

First quarter 2023 earnings released: CA$0.11 loss per share (vs CA$0.22 profit in 1Q 2022)

Insufficient new directors

Investor sentiment improved over the past week

Full year 2022 earnings released: EPS: CA$0.31 (vs CA$0.61 loss in FY 2021)

Imperial Ginseng Products Ltd., Annual General Meeting, Dec 07, 2022

Less than half of directors are independent

Chairman exercised options to buy CA$50k worth of stock.

Less than half of directors are independent

Third quarter 2022 earnings released: CA$0.05 loss per share (vs CA$0.03 loss in 3Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Investor sentiment improved over the past week

We Think Imperial Ginseng Products' (CVE:IGP) Robust Earnings Are Conservative

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: CA$0.61 loss per share (vs CA$1.00 loss in FY 2020)

Less than half of directors are independent

Third quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.11 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CA$0.13 (vs CA$0.07 loss in 2Q 2020)

New 90-day high: CA$0.55

How Much is Imperial Ginseng Products' (CVE:IGP) CEO Getting Paid?

New 90-day high: CA$0.37

First quarter 2021 earnings released: CA$0.57 loss per share

Full year earnings released - CA$1.00 loss per share

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Discover healthy companies